MedTrace Logo

Effects of an Aerobic Exercise Program on Cardiovascular Risk in Patients With Chronic Kidney Disease or Rheumatoid Arthritis

NCT07469540 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2026-03-13

No results posted yet for this study

Summary

The goal of this clinical trial is to determine whether an aerobic exercise program can reduce cardiovascular risk in patients with systemic inflammation, such as those with rheumatoid arthritis and chronic kidney disease.

The main questions this study aims to address are:

* Does an individualized aerobic exercise program reduce cardiovascular risk, as assessed arterial stiffness and endothelial function ?
* What are the effects of this exercise program on inflammation and immunosenescence?

Researchers will compare an individualized aerobic exercise program with a therapeutic education program (consisting of educational phone calls only) and a control group with no intervention.

Participants will:

* Perform three physical activity sessions per week for six weeks (45-minute sessions at 60-80% of heart rate reserve);
* Attend clinic visits at baseline, after the 6-week intervention, and at a 6-week follow-up after the intervention;
* Undergo assessments including pulse wave velocity, hyperemic reactivity, and blood analyses.

Conditions

Interventions

BEHAVIORAL

Aerobic exercise program

Aerobic exercise program during 6 weeks, with 3 sessions / week. Each session includes 45 minutes of ergocycle, with 9 cycles of 4 minutes at 60% of heart rate and 1 minute at 80%.

BEHAVIORAL

Therapeutic education

Therapeutic education for 6 weeks, with one telephone call per week. Each call includes advices and exchanges to improve physical activity level.

Sponsors & Collaborators

  • UMR1098, EFS BFC, BESANCON

    collaborator UNKNOWN

  • Centre Hospitalier Universitaire de Besancon

    collaborator OTHER

  • Jérôme Bouchan

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-16
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07469540 on ClinicalTrials.gov